Abstract: The present invention relates to improvements in compositions containing peptides that are ligands of the GHS receptor, or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and methods of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of H-Inp-D-Bal-D-Trp-Phe-Apc-NH2, which is a ligand of the GHS receptor and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms an in situ depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol with an average molecular weight of lower than 1000.
Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
Type:
Application
Filed:
January 18, 2016
Publication date:
July 21, 2016
Applicant:
Ipsen Pharma S.A.S.
Inventors:
Zheng Xin Dong, John E. Taylor, Rakesh Datta, Michael DeWitt Culler
Abstract: The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal 1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.
Type:
Grant
Filed:
September 29, 2009
Date of Patent:
July 5, 2016
Assignees:
IPSEN PHARMA S.A.S., COMMISSARIAT A L'ENERGIE ATOMIQUE (CEA), LE CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (CNRS)
Inventors:
Marie-Thérèse Paternostre, Jean-Christophe Cintrat, Céline Valery, Stéphane Roux, Bernard Rousseau, Maarten Ijsselstijn, Roland Cherif-Cheikh, Franck Artzner
Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
Type:
Application
Filed:
February 29, 2016
Publication date:
June 23, 2016
Applicant:
Ipsen Pharma S.A.S.
Inventors:
Zheng Xin DONG, Daniel B. DEOLIVEIRA, Jeanne Mary COMSTOCK
Abstract: The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
Abstract: The invention relates to a process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and to pharmaceutical compositions prepared according to the process. In a preferred aspect the process comprises the steps of combining lanreotide acetate and acetic acid, lyophilizing the resulting mixture only once, and hydrating the lyophilizate. Acetic acid may be added to a desired pH during the final step of the process.
Type:
Grant
Filed:
January 11, 2011
Date of Patent:
May 31, 2016
Assignee:
IPSEN PHARMA S.A.S.
Inventors:
Martin Montes, Thomas Ciaran Loughman, Chantal Roume, Roland Cherif-Cheikh
Abstract: The present invention relates to improvements in compositions containing peptides that are ligands of one or more of the melanocortin receptors (MC-R), or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 which is a ligand of the melanocortin receptor subtype 4 (MC4-R), and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms a depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol (PEG) with an average molecular weight of lower than 1000.
Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
Type:
Grant
Filed:
September 12, 2013
Date of Patent:
March 29, 2016
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
Abstract: The present invention relates to at least one botulinum neurotoxin for treatment or prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
Type:
Grant
Filed:
February 7, 2014
Date of Patent:
February 16, 2016
Assignee:
IPSEN PHARMA S.A.S.
Inventors:
Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
Type:
Application
Filed:
September 3, 2015
Publication date:
December 24, 2015
Applicant:
IPSEN PHARMA S.A.S.
Inventors:
Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
Abstract: The invention relates to a method for determining the kinetics of action of a cholinergic neurotoxin as well as a method for determining the quantity of neurotoxin in a sample.
Type:
Grant
Filed:
August 11, 2006
Date of Patent:
November 3, 2015
Assignee:
IPSEN PHARMA S.A.S.
Inventors:
José-Antonio Camara-Ferrer, Michael Auguet, Pierre-Etienne Chabrier De Lassauniere
Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
Type:
Application
Filed:
October 31, 2013
Publication date:
October 15, 2015
Applicant:
IPSEN PHARMA S.A.S.
Inventors:
Zheng Xin DONG, Yeelana SHEN, Sun Hyuk Kim
Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
Type:
Grant
Filed:
November 5, 2008
Date of Patent:
October 13, 2015
Assignees:
Ipsen Pharma S.A.S., Louisiana State University
Inventors:
Heather A. Halem, Michael Dewitt Culler, Andrew A. Butler
Abstract: The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.
Abstract: There is provided a series of glucose-dependent insulinotropic polypeptide analog compounds, pharmaceutical compositions, and the use of the GIP polypeptide analog compounds as GIP-receptor agonists or antagonists for the treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
Abstract: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
Abstract: The present invention relates to novel somatostatin analogs, dimers thereof, and methods of using the same to treat various diseases. Naturally occurring somatostatins (SSTs), which are also known as somatotropin release-inhibiting factors (SRIFs), have diverse biological effects in many cells and organs 10 throughout the body. They are produced by normal endocrine, gastrointestinal, immune and neuronal cells, as well as by certain tumors (Patel, Y. C, Frontiers in Neuroendocrinology, 20(3): 157-198 (1999); Froidevaux, et al., Biopolymers, 66(3): 161-83 (2002)).
Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
Abstract: The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.